| scholarly article | Q13442814 |
| P356 | DOI | 10.1002/ART.1780391210 |
| P698 | PubMed publication ID | 8961906 |
| P50 | author | B. J. Manaster | Q110085969 |
| P2093 | author name string | Cush JJ | |
| Anderson RJ | |||
| Clegg DO | |||
| Cannon GW | |||
| Ward JR | |||
| Weisman MH | |||
| Luggen ME | |||
| Mahowald ML | |||
| Henderson WG | |||
| Ward RH | |||
| Taylor T | |||
| Schumacher HR Jr | |||
| Cohen MR | |||
| Vasey FB | |||
| Budiman-Mak E | |||
| Reda DJ | |||
| Alepa FP | |||
| Haakenson CM | |||
| Makkena R | |||
| Blackburn WD | |||
| Mejias E | |||
| Silverman SL | |||
| P433 | issue | 12 | |
| P921 | main subject | sulfasalazine | Q420035 |
| veteran | Q193891 | ||
| placebo | Q269829 | ||
| P304 | page(s) | 2013-2020 | |
| P577 | publication date | 1996-12-01 | |
| P1433 | published in | Arthritis & Rheumatology | Q4797636 |
| P1476 | title | Comparison of sulfasalazine and placebo in the treatment of psoriatic arthritis. A Department of Veterans Affairs Cooperative Study | |
| P478 | volume | 39 |
| Q95359159 | Q95359159 |
| Q95359176 | Q95359176 |
| Q95359604 | Q95359604 |
| Q40625154 | A patient-initiated DMARD self-monitoring service for people with rheumatoid or psoriatic arthritis on methotrexate: a randomised controlled trial |
| Q35554193 | A randomised placebo controlled trial of delipidated, deglycolipidated Mycobacterium vaccae as immunotherapy for psoriatic arthritis |
| Q36096798 | A randomized placebo-controlled trial of methotrexate in psoriatic arthritis |
| Q38236514 | A review of disease activity measures for psoriatic arthritis: what is the best approach? |
| Q42685943 | Alefacept treatment in psoriatic arthritis: reduction of the effector T cell population in peripheral blood and synovial tissue is associated with improvement of clinical signs of arthritis |
| Q82352190 | Analgesic and disease modifying effects of interferential current in psoriatic arthritis |
| Q33780215 | Antibiotics for the treatment of rheumatologic syndromes |
| Q88495313 | Análisis Costo-Utilidad Del Uso De Adalimumab, Etanercept E Infliximab Para El Tratamiento De La Artritis Psoriásica En Uruguay |
| Q37741879 | Application of the GRAPPA psoriatic arthritis treatment recommendations in clinical practice |
| Q38616811 | Apremilast for the treatment of psoriatic arthritis |
| Q38710469 | Assessing disease activity in psoriasis and psoriatic arthritis: impact on management and therapy |
| Q55109332 | Assessing the effectiveness of synthetic and biologic disease-modifying antirheumatic drugs in psoriatic arthritis - a systematic review. |
| Q34620257 | Biologics in the management of psoriasis. |
| Q49086643 | Bowel inflammation and the spondyloarthropathies |
| Q81646326 | Classification and categorisation of psoriatic arthritis |
| Q48339070 | Clinical Features of Psoriatic Arthritis: a Comprehensive Review of Unmet Clinical Needs. |
| Q89074054 | Clinical management of psoriatic arthritis |
| Q26995307 | Clinical outcomes in psoriatic arthritis: A systematic literature review |
| Q37031662 | Clinical potential of apremilast in the treatment of psoriatic arthritis |
| Q42955288 | Comparison of different outcome measures for psoriatic arthritis in patients treated with infliximab or placebo |
| Q45334709 | Comparison of sulfasalazine and placebo for the treatment of axial and peripheral articular manifestations of the seronegative spondylarthropathies: a Department of Veterans Affairs cooperative study |
| Q49850238 | Cost-effectiveness analysis of secukinumab for the treatment of active psoriatic arthritis: a Canadian perspective |
| Q51289760 | Cost-efficacy of biologic therapies for psoriatic arthritis from the perspective of the Taiwanese healthcare system. |
| Q36780933 | Current treatment for psoriatic arthritis and other spondyloarthritides |
| Q35210206 | Current treatment of psoriatic arthritis |
| Q43018087 | Cytokine blockers in psoriatic arthritis. |
| Q36594215 | Dactylitis: pathogenesis and clinical considerations |
| Q38165235 | Diagnosing and treating psoriatic arthritis: an update |
| Q34158095 | Diagnosis and management of psoriatic arthritis |
| Q34485175 | Discriminant validity, responsiveness and reliability of the arthritis-specific Work Productivity Survey assessing workplace and household productivity in patients with psoriatic arthritis |
| Q48960736 | Disease activity in psoriatic arthritis (PsA): defining remission and treatment success using the DAPSA score |
| Q36577467 | Drug insight: anti-tumor-necrosis-factor therapy for ankylosing spondylitis |
| Q91934535 | Drug repurposing to improve treatment of rheumatic autoimmune inflammatory diseases |
| Q37058444 | Economic burden of psoriatic arthritis |
| Q37465550 | Effect of certolizumab pegol on signs and symptoms in patients with psoriatic arthritis: 24-week results of a Phase 3 double-blind randomised placebo-controlled study (RAPID-PsA). |
| Q34027624 | Effectiveness and safety of adalimumab in patients with ankylosing spondylitis or psoriatic arthritis and history of anti-tumor necrosis factor therapy |
| Q55315590 | Effectiveness and safety of golimumab in patients with rheumatoid arthritis, psoriatic arthritis and ankylosing spondylitis under real-life clinical conditions: non-interventional GO-NICE study in Germany. |
| Q33566374 | Effectiveness of adalimumab in treating patients with active psoriatic arthritis and predictors of good clinical responses for arthritis, skin and nail lesions |
| Q44450869 | Effects of adalimumab therapy on musculoskeletal manifestations and health-related quality of life in patients with active psoriatic arthritis |
| Q38785383 | Efficacy and safety of etanercept in psoriasis and psoriatic arthritis in the PRESTA study: analysis in patients from Central and Eastern Europe |
| Q46467386 | Efficacy and safety of secukinumab, a fully human anti-interleukin-17A monoclonal antibody, in patients with moderate-to-severe psoriatic arthritis: a 24-week, randomised, double-blind, placebo-controlled, phase II proof-of-concept trial |
| Q34731307 | Emerging role of anti-tumor necrosis factor therapy in rheumatic diseases |
| Q35116180 | Etanercept in psoriatic arthritis |
| Q74265787 | Etanercept in the treatment of psoriatic arthritis and psoriasis: a randomised trial |
| Q34991484 | Etanercept: an updated review of its use in rheumatoid arthritis, psoriatic arthritis and juvenile rheumatoid arthritis |
| Q35190112 | Evaluation and management of psoriatic arthritis: the role of biologic therapy |
| Q37979273 | Golimumab for the treatment of psoriatic arthritis: a NICE single technology appraisal |
| Q38691418 | Group for Research and Assessment of Psoriasis and Psoriatic Arthritis 2015 Treatment Recommendations for Psoriatic Arthritis |
| Q36032569 | Guideline for anti-TNF-alpha therapy in psoriatic arthritis |
| Q35569003 | Heel pain due to psoriatic arthritis in a 50 year old recreational male athlete: case report |
| Q35555905 | Infliximab improves signs and symptoms of psoriatic arthritis: results of the IMPACT 2 trial |
| Q35760193 | Infliximab maintains a high degree of clinical response in patients with active psoriatic arthritis through 1 year of treatment: results from the IMPACT 2 trial |
| Q33907780 | Interventions for psoriatic arthritis. |
| Q38206551 | Investigational drugs for treating psoriatic arthritis |
| Q36407354 | Juvenile idiopathic arthritis: current and future treatment options |
| Q41587392 | Juvenile-onset spondyloarthropathies |
| Q43673954 | Leflunomide in psoriatic arthritis: results from a large European prospective observational study |
| Q36150789 | Leflunomide: long-term clinical experience and new uses |
| Q92737255 | Long-term effectiveness of tumour necrosis factor-α inhibitor treatment for psoriatic arthritis in the UK: a multicentre retrospective study |
| Q26783506 | Making the next steps in psoriatic arthritis management: current status and future directions |
| Q37930978 | Management of psoriatic arthritis from the view of the dermatologist |
| Q27693878 | Managing patients with psoriatic disease: the diagnosis and pharmacologic treatment of psoriatic arthritis in patients with psoriasis |
| Q37023883 | Metabolic profiling predicts response to anti-tumor necrosis factor α therapy in patients with rheumatoid arthritis |
| Q94336562 | Methotrexate for psoriatic arthritis |
| Q34999557 | Miscellaneous treatments, I: sulfasalazine and pentoxifylline: unapproved uses, dosages, or indications |
| Q35164736 | Novel approaches in the treatment of ankylosing spondylitis and other spondyloarthritides |
| Q38211315 | Novel methods of measuring clinical outcomes from psoriasis and psoriatic arthritis clinical trials |
| Q92098180 | Observational study of inflammatory arthritis treatment by etanercept originator switched to an etanercept biosimilar |
| Q37619717 | Outcome measures in inflammatory rheumatic diseases |
| Q36140811 | Outcome measures in psoriatic arthritis |
| Q36208083 | Outcome measures in psoriatic arthritis clinical trials |
| Q35116177 | Overview of the use of the anti-TNF agent infliximab in chronic inflammatory diseases |
| Q90893942 | Pathophysiology, assessment and treatment of psoriatic dactylitis |
| Q38822369 | Patient-Reported Outcomes in Psoriatic Arthritis. |
| Q46876696 | Pattern of bone erosion and bone proliferation in psoriatic arthritis hands: a high-resolution computed tomography and radiography follow-up study during adalimumab therapy |
| Q31038425 | Performance of response criteria for assessing peripheral arthritis in patients with psoriatic arthritis: analysis of data from randomised controlled trials of two tumour necrosis factor inhibitors |
| Q85849691 | Periodontal disease in patients with psoriatic arthritis |
| Q46598057 | Pharmaceutical care of patients with rheumatoid and psoriatic arthritis receiving etanercept |
| Q94322276 | Phosphodiesterase 4 inhibitors for psoriatic arthritis |
| Q77803164 | Psoriatic arthritis |
| Q43056875 | Psoriatic arthritis and etanercept |
| Q35579462 | Psoriatic arthritis assessment tools in clinical trials |
| Q35579450 | Psoriatic arthritis therapy: NSAIDs and traditional DMARDs. |
| Q38668527 | Psoriatic arthritis treatment regimens, therapy duration and reasons for cessation in the biologics era: a multi-centre Australian study |
| Q44557662 | Psoriatic arthritis. Treatment outcome parameters |
| Q35579437 | Psoriatic arthritis: epidemiology, clinical features, course, and outcome |
| Q24813979 | Psoriatic arthritis: pathogenesis and novel immunomodulatory approaches to treatment |
| Q37758453 | Psoriatic arthritis: pharmacotherapy update |
| Q35902691 | Psoriatic arthritis: prevalence, diagnosis, and review of therapy for the dermatologist. |
| Q37679286 | Real-life experience of using conventional disease-modifying anti-rheumatic drugs (DMARDs) in psoriatic arthritis (PsA). Retrospective analysis of the efficacy of methotrexate, sulfasalazine, and leflunomide in PsA in comparison to spondyloarthritid |
| Q35551412 | Repeated infusions of infliximab, a chimeric anti-TNFalpha monoclonal antibody, in patients with active spondyloarthropathy: one year follow up |
| Q37541327 | Review: Enthesitis: New Insights Into Pathogenesis, Diagnostic Modalities, and Treatment |
| Q35026454 | Safety and clinical efficacy of golimumab in the treatment of arthritides |
| Q34595156 | Safety and efficacy of disease-modifying anti-rheumatic agents: focus on the benefits and risks of etanercept |
| Q36040052 | Science of assessment |
| Q46129663 | Singapore Chapter of Rheumatologists consensus statement on the eligibility for government subsidy of biologic disease modifying anti-rheumatic agents for the treatment of psoriatic arthritis. |
| Q34309710 | Spondylarthropathies: options for combination therapy |
| Q34613907 | Spondyloarthritides: evolving therapies |
| Q35210198 | Spondyloarthropathy for practicing rheumatologists: diagnosis, indication for disease-controlling antirheumatic therapy, and evaluation of the response |
| Q31036925 | Survival of TNF antagonists in spondylarthritis is better than in rheumatoid arthritis. Data from the Spanish registry BIOBADASER. |
| Q42675432 | Sustained Clinical Response in Psoriatic Arthritis Patients Treated with Anti-TNF Agents: A 5-year Open-Label Observational Cohort Study |
| Q36013849 | Switching tumour necrosis factor alpha antagonists in patients with ankylosing spondylitis and psoriatic arthritis: an observational study over a 5-year period |
| Q24240905 | TNF-alpha inhibitors for psoriatic arthritis |
| Q38393840 | The Efficacy and Safety of Clazakizumab, an Anti-Interleukin-6 Monoclonal Antibody, in a Phase IIb Study of Adults With Active Psoriatic Arthritis |
| Q33916770 | The GOLMePsA study protocol: an investigator-initiated, double-blind, parallel-group, randomised, controlled trial of GOLimumab and methotrexate versus methotrexate in early diagnosed psoriatic arthritis using clinical and whole body MRI outcomes |
| Q38644022 | The impact of disease severity, illness beliefs and coping strategies on outcomes in psoriatic arthritis. |
| Q40826149 | The spondylarthropathies: classification and diagnosis. Do we need new terminologies? |
| Q24806367 | Therapy of ankylosing spondylitis and other spondyloarthritides: established medical treatment, anti-TNF-alpha therapy and other novel approaches |
| Q36139268 | Traditional and newer therapeutic options for psoriatic arthritis: an evidence-based review |
| Q38670583 | Treating to target in psoriatic arthritis: how to implement in clinical practice |
| Q38204241 | Treatment of psoriatic arthritis with anti-TNF agents: a systematic review and meta-analysis of efficacy, effectiveness and safety |
| Q39003610 | Treatment of psoriatic arthritis with traditional DMARD's and novel therapies: approaches and recommendations. |
| Q37008829 | Tumor necrosis factor as a therapeutic target of rheumatologic disease |
| Q35834811 | Tumor necrosis factor-alpha in psoriasis and psoriatic arthritis: a clinical, genetic, and histopathologic perspective |
| Q34550167 | Tumour necrosis factor (TNF) in psoriatic arthritis: pathophysiology and treatment with TNF inhibitors |
| Q36080668 | Understanding psoriatic arthritis |
| Q43061552 | Update in treatment options for psoriatic arthritis |
| Q35638252 | Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2006. |
| Q35579352 | Updated consensus statement on biological agents, specifically tumour necrosis factor alpha (TNFalpha) blocking agents and interleukin-1 receptor antagonist (IL-1ra), for the treatment of rheumatic diseases, 2004. |
| Q35579517 | Updated consensus statement on biological agents, specifically tumour necrosis factor {alpha} (TNF{alpha}) blocking agents and interleukin-1 receptor antagonist (IL-1ra), for the treatment of rheumatic diseases, 2005 |
| Q41917310 | Use of disease-modifying antirheumatic drugs in patients with psoriatic arthritis |
| Q92737085 | What does evidence-based medicine tell us about treatments for different subtypes of psoriatic arthritis? A systematic literature review on randomized controlled trials |
| Q74423376 | Which second-line treatments are optimal in psoriatic arthritis? |
| Q81141982 | [Etanercept. An effective TNF alpha-antagonist in the treatment of psoriatic arthritis and chronic plaque psoriasis] |
| Q82663598 | [Outcome parameters for use in psoriatic arthritis] |
| Q88420740 | [Psoriatic arthritis : Current therapeutic standards] |
| Q52927228 | [Psoriatic arthritis : Overview of drug therapy options and administration characteristics]. |
| Q53760739 | [Psoriatic arthritis : Overview of drug therapy options and administration characteristics]. |
| Q85054900 | [Psoriatric arthritis - a permanent challenge for rheumatologists and patients: part 2: imaging diagnostics, classification and therapy] |
| Q79356110 | [Therapy for secondary arthropathies: from psoriasis and Reiter's disease to hemochromatosis] |
| Q85882358 | [Therapy of psoriatic arthritis] |
| Q90442686 | [Treatment of psoriatic arthritis : Are there differential indications?] |
| Q26862017 | Measures of psoriatic arthritis: Tender and Swollen Joint Assessment, Psoriasis Area and Severity Index (PASI), Nail Psoriasis Severity Index (NAPSI), Modified Nail Psoriasis Severity Index (mNAPSI), Mander/Newcastle Enthesitis Index (MEI), Leeds En |
Search more.